TG Therapeutics (TGTX) PT Lowered to $13 at Goldman Sachs
Tweet
Share
E-mail
Get Alerts TGTX Hot Sheet
Price: $56.19 -2.16%
Rating Summary:
12 Buy, 1 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 11 | New: 53
Rating Summary:
12 Buy, 1 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 11 | New: 53
Join SI Premium – FREE
Goldman Sachs analyst Corinne Jenkins lowered the price target on TG Therapeutics (NASDAQ: TGTX) to $13.00 (from $26.00) while maintaining a Sell rating as the ODAC raises new questions on benefit/risk of U2 in CLL.
"Timing of approval decision likely delayed, approvability of U2 in CLL in question," the analyst notes.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertex (VRTX) PT Raised to $615 at UBS
- Lightspeed POS Inc. (LSPD)Assumed at Equalweight at Morgan Stanley
- NiSource (NI) PT Lowered to $45 at BMO Capital
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
